trending Market Intelligence /marketintelligence/en/news-insights/trending/SqJPf78XX9P5Pof3Lw58WA2 content esgSubNav
In This List

United Therapeutics postpones US launch of implantable pump

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


United Therapeutics postpones US launch of implantable pump

United Therapeutics Corp. postponed the U.S. launch of its RemoSynch implantable pump for use with the Remodulin therapy for treating pulmonary arterial hypertension.

The system will now be available in 2018 due to regulatory delays. The company developed the RemoSynch system with Medtronic Inc.'s proprietary intravascular infusion catheter, implantable infusion pump and related infusion system components to deliver the drug to treat patients.

United Therapeutics and Medtronic are pursuing parallel regulatory filings for the device and the treatment.